A new add-on therapy administered every six months targets key inflammatory pathways in asthma and chronic rhinosinusitis ...

GSK on Tuesday said Japan’s Ministry of Health, Labour and Welfare approved Exdensur, also known as depemokimab, for patients with bronchial asthma whose symptoms cannot be controlled with existing ...

Lyra Therapeutics is abandoning work on its rhinosinusitis treatment and laying off its remaining employees.

Nasal sprays can help treat congestion and other symptoms from allergies or a cold. There are three main types of nasal ...

A new Australian study has found that a simple saline nasal spray could help many children breathe and sleep better, ...

Studies show that smell loss with age may reflect more serious underlying problems, and is even linked to how long we're ...

Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further development of LYR-210, the Company’s lead product candidate ...

Another common reason for nosebleeds is “digital manipulation, which is a nice way of saying nose picking or scratching your nose”, says Loftus. The nose is delicate, and even a light bump or scratch ...

The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial ...

Lyra Therapeutics is suspending further development of its lead product candidate for the treatment of chronic rhinosinusitis and taking steps to cut costs, including workforce reductions that will ...